rasagiline / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 72 Diseases   9 Trials   9 Trials   596 News 


«12345678»
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp
    Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report (Poster Station: 1) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_956;    
    The patient had self-discontinued amantadine and rasagiline believing they could cause congenital abnormalities in the baby... This case highlights the importance of robust recognition of ICDs and the possibility that they can present in a unique form such as that of phantom pregnancy in PD.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Bullous skin lesions following introduction of safinamide in a woman with Parkinson’s disease (Poster Station: 1) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_955;    
    Whereas no histopathological examination was performed to confirm the diagnosis, it nevertheless raises the possibility that safinamide may cause drug-induced pemphigoid, at least in some individuals who previously have had this condition. Further case reports like this one, with histopathological confirmation, are necessary to confirm this possibility.
  • ||||||||||  Nourianz (istradefylline) / Kyowa Kirin
    Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease (Poster Station: 23) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_769;    
    Drugs of interest included dopamine agonists, MAO-B inhibitors, COMT inhibitors, istradefylline, and amantadine...Ropinirole, rasagiline, and istradefylline were the most studied adjunctive treatments with 7, 6, and 4 publications, respectively... Early assessment of the relative comparability of these randomized controlled trials suggests that it will be feasible to perform future indirect treatment comparative analyses across adjunctive treatments in PD.
  • ||||||||||  rasagiline / Generic mfg.
    Retrospective data, Review, Journal:  Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Sep 13, 2022   
    The incidence of TEAEs did not differ between treatments (risk ratio: 1.13, 95% CI: 0.98-1.30, p = 0.093). This meta-analysis further indicated the superiority of rasagiline/levodopa in improving motor and nonmotor symptoms of Parkinson's disease, with a similar safety profile to that of levodopa in Parkinson's disease with motor fluctuations.
  • ||||||||||  tofersen (BIIB067) / Biogen
    Journal:  Clinical studies in amyotrophic lateral sclerosis. (Pubmed Central) -  Sep 10, 2022   
    A phase III study with tofersen was negative but nevertheless yielded promising results. Important developments regarding the design of clinical ALS studies include the implementation of neurofilament light chain (NfL) levels as a standard outcome parameter and the consideration of progression rate for therapeutic response and stratification.
  • ||||||||||  selegiline / Generic mfg., rasagiline / Generic mfg.
    Review, Journal:  Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies. (Pubmed Central) -  Aug 30, 2022   
    Clinically approved MAO inhibitors for example selegiline, rasagiline, clorgyline, pargyline etc. are irreversible in nature and cause some adverse effects while recently studied reversible MAO inhibitors are devoid of harmful effects of old monoamine oxidase inhibitors. In this review article we have listed various synthesized molecules containing different moieties like coumarin, chalcone, thiazole, thiourea, caffeine, pyrazole, chromone etc. along with their activity, mode of action, structure activity relationship and molecular docking studies.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp, Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson's Patients with Motor Fluctuations (A7) -  Jul 18, 2022 - Abstract #EAN2022EAN_1306;    
    All treatments were more effective than placebo in reducing mean change from baseline OFF-time in PD patients with MF, with COMT inhibitors showing more efficacious trends than MAO-B inhibitors. Tolcapone and opicapone appeared to be the best performing drugs.
  • ||||||||||  Cognex (tacrine) / Shionogi
    Journal:  New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity. (Pubmed Central) -  Jul 17, 2022   
    Moreover, in vitro results showed that conjugation of MAP with drugs led to a higher decrease in cell viability of a neuroblastoma cell line and Caco-2 cell line, more than MAP alone. Furthermore, NLC encapsulation contributed to higher cellular delivery and enhanced toxic activity at lower concentrations when compared with free or co-administration drug-MAP conjugate.
  • ||||||||||  rasagiline / Generic mfg.
    Journal:  Polyphenolic Glycosides from the Fruits Extract of Lycium ruthenicum Murr and Their Monoamine Oxidase B Inhibitory and Neuroprotective Activities. (Pubmed Central) -  Jul 9, 2022   
    Compounds 1, 2, and 16 exhibited moderate inhibitory activity of monoamine oxidase B (MAO-B), while compounds 1 (50 μM) and 2 (100 μM) displayed significant neuroprotective effects (69.22 and 72.38% of cell viability, respectively) in the 6-hydroxydopamine-induced injury of the PC12 cell model (54.41%), comparable to the positive drug rasagiline (70.45%)...This is the first report on phenolic glycosides from the fruits ofL. ruthenicum Murr that possess both significant MAO-B inhibitory and neuroprotective effects, indicating the promising potential of the fruits for the development of health care products and even therapeutic agents for the treatment of Parkinson's disease and other neurodegenerative diseases.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Review, Journal:  A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. (Pubmed Central) -  Jun 15, 2022   
    Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson's disease, an option which is too often not appreciated properly.
  • ||||||||||  selegiline / Generic mfg., rasagiline / Generic mfg.
    Journal:  The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. (Pubmed Central) -  May 12, 2022   
    Interestingly, dialysis studies found that 2-PAT is a reversible MAO-A inhibitor, while acting as an inactivator of MAO-B. Since reversible MAO-A inhibitors are much less liable to potentiate tyramine-induced side effects than MAO-A inactivators, it is reasonable to suggest that 2-PAT could be a useful and safe therapeutic agent for disorders such as Parkinson's disease and depression.
  • ||||||||||  rasagiline / Generic mfg.
    Journal:  Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. (Pubmed Central) -  Apr 5, 2022   
    MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.
  • ||||||||||  rasagiline / Generic mfg., amphetamine / Generic mfg.
    Journal:  Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease. (Pubmed Central) -  Apr 5, 2022   
    In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy. The results indicate that A1R agonists and drugs promoting a "knot" conformation of α-syn can cause α-synucleinopathy and increase neuronal degeneration, whereas A1R antagonists and drugs promoting a "loop" conformation of α-syn can be harnessed for possible neuroprotective therapies to decrease α-synucleinopathy in PD.
  • ||||||||||  Review, Journal:  Understanding flow chemistry for the production of active pharmaceutical ingredients. (Pubmed Central) -  Mar 5, 2022   
    The review majorly emphasizes on the recent developments in the flow synthesis of pharmaceutically important products in last five years including flibanserin, imatinib, buclizine, cinnarizine, cyclizine, meclizine, ribociclib, celecoxib, SC-560 and mavacoxib, efavirenz, fluconazole, melitracen HCl, rasagiline, tamsulosin, valsartan, and hydroxychloroquine. Critical steps and new development in the flow synthesis of selected compounds are also discussed.
  • ||||||||||  rasagiline / Generic mfg.
    Journal:  Rasagiline Withdrawal Syndrome in Parkinson's Disease. (Pubmed Central) -  Feb 26, 2022   
    The syndrome was mainly characterized by prominent psychiatric disorders (depression, anxiety with panic attacks, dysphoria, and agitation) associated with fatigue, generalized pain, and autonomic manifestations (closely resembling symptoms of DAWS). In our opinion, this report suggests the importance of closely monitoring PD patients undergoing rasagiline suspension for withdrawal symptoms and provides interesting points of reflection on the role of rasagiline and other MAO-B inhibitors in mood disorders.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Retrospective data, Journal:  Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. (Pubmed Central) -  Feb 9, 2022   
    There was no report of adverse events. Findings from this retrospective, exploratory study suggest that safinamide 100 mg may produce more powerful benefit that rasagiline 1 mg as add-on to levodopa in fluctuating PD patients, possibly because of the bimodal mechanism of action of the former drug.
  • ||||||||||  tolcapone / Generic mfg., bromocriptine / Generic mfg., rasagiline / Generic mfg.
    Review, Journal:  Search for safer and potent natural inhibitors of Parkinson's disease. (Pubmed Central) -  Feb 5, 2022   
    In this review, we have compiled phytocompounds that have shown potent activity against some of the most important targets for antiparkinsonian therapy. These compounds have exhibited activities that transcend the limits of simply attenuating mitochondrial oxidative stress and have opened doors to the discovery of novel lead compounds for newer, efficacious antiparkinsonian therapies with wider therapeutic windows.
  • ||||||||||  rasagiline / Generic mfg.
    Clinical, Review, Journal, IO biomarker:  Possible inflammatory mechanisms and predictors of Parkinson's disease patients with fatigue (Brief Review). (Pubmed Central) -  Jan 28, 2022   
    At present, its management mainly includes medical treatment (levodopa, dopamine receptor agonists, rasagiline, and antidepressants) and non-medical treatment (acupuncture and yoga). Thus, it is of great significance to be able to practice early detection and intervention in fatigue and improve the prognosis of patients with PD.
  • ||||||||||  rasagiline / Generic mfg.
    Journal:  Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline. (Pubmed Central) -  Jan 11, 2022   
    The best mutant Q237A from AcRedAm could synthesize (R)-rasagiline with >99% enantiomeric excess with moderate conversion. The features of AcRedAm and BaRedAm highlight their potential for further study and expand the biocatalytic toolbox for industrial applications.
  • ||||||||||  rasagiline / Generic mfg.
    Mao-b inhibition facilitates α-synuclein secretion via an abc transporter-mediated pathway and delays its aggregation (Virtual Only) -  Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_1993;    
    These findings suggest that MAO-B inhibition modulates the intracellular clearance of detergent-insoluble α-syn via the ABC transporter-mediated non-classical secretion pathway in vitro, and temporarily delays the formation and transmission of α-syn aggregates in rat models. We propose a new function of MAO-B inhibition that modulates α-syn secretion and aggregation in PD treatment.
  • ||||||||||  rasagiline / Generic mfg.
    Preclinical, Journal:  Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. (Pubmed Central) -  Dec 16, 2021   
    Finally, using the rat model of rotenone-induced Parkinsonism, we demonstrated that the topical application of RSM-MEG was equally effective in reversing PD symptoms when compared to oral RSM therapy. Thus, our study confirmed the feasibility and potential of transdermal delivery of RSM via simple topical application of RSM-MEG, and this approach could be an alternative therapeutic intervention for the treatment of Parkinson's disease.